Troxevasin - instructions for use, dose, side effects, contraindications

Capsule shell: capsule body - dye quinoline yellow (E 104) 0.9%, dye sunset yellow (E 110) 0.039%,titanium dioxide (E 171) 3%, gelatin up to 100%; lid capsule - dye quinoline yellow (E 104) 0.9%, dye sunset yellow (E, 110) 0.039%, titanium dioxide (E 171) 3%, gelatin to 100%.

Description:Solid cylindrical gelatin capsules number 1, body - yellow, the lid is yellow.

Content of capsules: powder from yellow to yellow-green color, conglomerates are allowed, which decompose when pressed.

Pharmacotherapeutic group:venotonic and venoprotective agent

ATX: & nbsp

C.05.C.A Bioflavonoids

C.05.C.A.04 Troxerutin

Pharmacodynamics:

Angioprotective agent, mainly affects the capillaries and veins. Reduces the pores between endothelial cells by modifying a fibrous matrix located between endothelial cells.

Inhibits aggregation and increases the degree of erythrocyte deformation; has anti-inflammatory effect.

With chronic venous insufficiency, Troxevasin® reduces the severity of edema, pain, seizures, trophic disorders, varicose ulcers. It alleviates the symptoms associated with hemorrhoids - pain, itching and bleeding.

Thanks to the beneficial effects of Troxevasin® on the permeability and resistance of the capillary walls, it helps slow the development of diabetic retinopathy.In addition, its effect on the rheological properties of the blood contributes to the prevention of microthrombosis of the retinal vessels.

Pharmacokinetics:

After intake, the absorption is about 10 - 15%. Maximum plasma concentrations are achieved on average 2 hours after admission, the therapeutic level in the plasma will persist for 8 hours. Metabolized in the liver, partially excreted unchanged in the urine (20-22% of the dose) and bile (60 -70% of the dose).

Indications:

Chronic venous insufficiency, postphlebitis syndrome, trophic disorders in varicose veins and trophic ulcers. As an auxiliary treatment after sclerotraping of veins and removal of varicose veins.

Hemorrhoids (pain, exudation, itching and bleeding).

Venous insufficiency and hemorrhoids during pregnancy, beginning with the second trimester.

As an auxiliary treatment for retinopathy in patients with diabetes mellitus, arterial hypertension and atherosclerosis.

Contraindications:Hypersensitivity to rutozides or other components of the drug. Pregnancy (first trimester). Peptic ulcer of stomach and duodenum, chronic gastritis in the phase of exacerbation, children's age to three years (solid dosage form).

Carefully:Carefully should be used (long-term use) for kidney failure, children's age from 3 to 15 years (see section "Special instructions").

Pregnancy and lactation:

To use Troxevasin® during pregnancy (II and III trimesters) and during lactation should be the case if the expected benefit for the mother prevails over the possible risk to the fetus and the baby.

Dosing and Administration:

Inside, with food; Capsules are swallowed whole, washed down with a sufficient amount of water. At the initial stage of treatment appoint 1 capsule (300 mg) 3 times a day.

The effect usually develops within 2 weeks, after which the treatment is continued at the same dose or reduced to a minimal maintenance dose of 600 mg, or suspended (and the effect is maintained for at least 4 weeks). The course of treatment is on average 3-4 weeks, the need for longer treatment is determined individually.

With diabetic retinopathy appoint 0.9 - 1.8 g / day.

Side effects:

Allergic reactions (for example, skin rash), nausea, diarrhea, heartburn, headache, "flushes" of blood to the face, erosive and ulcerative lesions of the gastrointestinal tract. They quickly disappear after discontinuation of treatment.

Overdose:

In case of an overdose, the following symptoms may appear: agitation, nausea, headache, flushing of blood to the face. In case of an overdose, patients should rinse the stomach, take Activated carbon, if necessary, start symptomatic treatment.

Interaction:

The action is enhanced by simultaneous intake of ascorbic acid.

Special instructions:

If the severity of the symptoms of the disease does not decrease during the period of the drug use, you should consult a doctor. The experience of using the drug in children under 15 years is not enough, which requires caution when it is used.

Effect on the ability to drive transp. cf. and fur:The intake of the drug has no effect on motor and mental reactions, does not interfere with the management of vehicles and work with mechanisms.

Form release / dosage:Capsules 300 mg.

Packaging:10 capsules per blister of PVC / Al foil or PVC / PVDC / Al foil.
By 5 or 10 blisters together with instructions for use in cardboard pack.

Storage conditions:

In a dry, the dark place at a temperature of no higher than 25 ° C.

Keep out of the reach of children!

Shelf life:

5 years.

Do not use after expiry date.

Terms of leave from pharmacies:Without recipe

Registration number:П N012713 / 01

Date of registration:25.03.2008

The owner of the registration certificate:Actavis PTS ehf GroupActavis PTS ehf Group Iceland

Manufacturer: & nbsp

BALKANPHARMA-RAZGRAD, AD Bulgaria

Representation: & nbspAktavis, Open Company Aktavis, Open Company

Information update date: & nbsp24.10.2015

Illustrated instructions

Instructions

Troxevasin® (Troxevasin®)